These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 17889350)

  • 21. Infectious complications in chronic graft-versus-host disease: a retrospective study of 145 recipients of allogeneic hematopoietic stem cell transplantation with reduced- and conventional-intensity conditioning regimens.
    Yamasaki S; Heike Y; Mori S; Fukuda T; Maruyama D; Kato R; Usui E; Koido K; Kim S; Tanosaki R; Tobinai K; Teshima T; Takaue Y
    Transpl Infect Dis; 2008 Jul; 10(4):252-9. PubMed ID: 18194371
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hematopoietic cell transplantation for children with acute lymphoblastic leukemia in second complete remission: similar outcomes in recipients of unrelated marrow and umbilical cord blood versus marrow from HLA matched sibling donors.
    Smith AR; Baker KS; Defor TE; Verneris MR; Wagner JE; Macmillan ML
    Biol Blood Marrow Transplant; 2009 Sep; 15(9):1086-93. PubMed ID: 19660721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of human leucocyte antigen disparity and graft lymphocytes on allogeneic engraftment and survival after umbilical cord blood transplant in adults.
    van Heeckeren WJ; Fanning LR; Meyerson HJ; Fu P; Lazarus HM; Cooper BW; Tse WW; Kindwall-Keller TL; Jaroscak J; Finney MR; Fox RM; Solchaga L; Forster M; Creger RJ; Laughlin MJ
    Br J Haematol; 2007 Nov; 139(3):464-74. PubMed ID: 17910637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytomegalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources.
    Walker CM; van Burik JA; De For TE; Weisdorf DJ
    Biol Blood Marrow Transplant; 2007 Sep; 13(9):1106-15. PubMed ID: 17697973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
    Huisman C; Meijer E; Petersen EJ; Lokhorst HM; Verdonck LF
    Biol Blood Marrow Transplant; 2008 Feb; 14(2):181-6. PubMed ID: 18215778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early (day -7) versus conventional (day -1) inception of cyclosporine-A for graft-versus-host disease prophylaxis after unrelated donor hematopoietic stem cell transplantation in children. Long-term results of an AIEOP prospective, randomized study.
    Lanino E; Rondelli R; Locatelli F; Messina C; Pession A; Balduzzi A; Favre C; Santarone S; Rabusin M; Pollichieni S; Cesaro S; Dini G;
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):741-8. PubMed ID: 19450759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Donor cell reaction to OKT3 as predictor of chronic graft-vs-host disease in hematopoietic stem cell recipients.
    Lindemann M; Ottinger HD; Elmaagacli AH; Trenschel R; Rebmann V; Beelen DW; Grosse-Wilde H
    Exp Hematol; 2006 Dec; 34(12):1753-8. PubMed ID: 17157173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth.
    Soncini E; Slatter MA; Jones LB; Hughes S; Hodges S; Flood TJ; Barge D; Spickett GP; Jackson GH; Collin MP; Abinun M; Cant AJ; Gennery AR
    Br J Haematol; 2009 Apr; 145(1):73-83. PubMed ID: 19222467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation.
    Ayuk F; Diyachenko G; Zabelina T; Wolschke C; Fehse B; Bacher U; Erttmann R; Kröger N; Zander AR
    Biol Blood Marrow Transplant; 2008 Aug; 14(8):913-9. PubMed ID: 18640575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diffuse alveolar hemorrhage and infection-associated alveolar hemorrhage following hematopoietic stem cell transplantation: related and high-risk clinical syndromes.
    Majhail NS; Parks K; Defor TE; Weisdorf DJ
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1038-46. PubMed ID: 17067910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of readmission in children receiving allogeneic hematopoietic stem cell transplantation: an institutional experience.
    Jaing TH; Tsay PK; Yang CP; Hung IJ; Wen YC; Tseng CK
    Transplant Proc; 2008 Dec; 40(10):3643-5. PubMed ID: 19100457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Delayed platelet recovery after allogeneic transplantation: a predictor of increased treatment-related mortality and poorer survival.
    Ramírez P; Brunstein CG; Miller B; Defor T; Weisdorf D
    Bone Marrow Transplant; 2011 Jul; 46(7):981-6. PubMed ID: 20921943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk-factor analysis for predicting progressive- or quiescent-type chronic graft-versus-host disease in a patient cohort with a history of acute graft-versus-host disease after allogeneic stem cell transplantation.
    Sohn SK; Kim DH; Baek JH; Kim JG; Lee KB; Lee KH; Lee JH; Choi SJ; Lee JH; Shin IH
    Bone Marrow Transplant; 2006 Apr; 37(7):699-708. PubMed ID: 16501588
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic graft-versus-host disease: a prospective cohort study.
    Arora M; Burns LJ; Davies SM; Macmillan ML; Defor TE; Miller WJ; Weisdorf DJ
    Biol Blood Marrow Transplant; 2003 Jan; 9(1):38-45. PubMed ID: 12533740
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research.
    Lazarus HM; Pérez WS; Klein JP; Kollman C; Bate-Boyle B; Bredeson CN; Gale RP; Geller RB; Keating A; Litzow MR; Marks DI; Miller CB; Douglas Rizzo J; Spitzer TR; Weisdorf DJ; Zhang MJ; Horowitz MM
    Br J Haematol; 2006 Mar; 132(6):755-69. PubMed ID: 16487177
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients.
    Mikulska M; Raiola AM; Bruno B; Furfaro E; Van Lint MT; Bregante S; Ibatici A; Del Bono V; Bacigalupo A; Viscoli C
    Bone Marrow Transplant; 2009 Sep; 44(6):361-70. PubMed ID: 19308042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hematopoietic transplantation from adult unrelated donors as treatment for acute myeloid leukemia.
    Sierra J; Martino R; Sánchez B; Piñana JL; Valcárcel D; Brunet S
    Bone Marrow Transplant; 2008 Mar; 41(5):425-37. PubMed ID: 18209727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Haploidentical Transplantation with Post-Transplant Cyclophosphamide versus Unrelated Donor Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
    Arcuri LJ; Aguiar MTM; Ribeiro AAF; Pacheco AGF
    Biol Blood Marrow Transplant; 2019 Dec; 25(12):2422-2430. PubMed ID: 31386903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results.
    Apisarnthanarax N; Donato M; Körbling M; Couriel D; Gajewski J; Giralt S; Khouri I; Hosing C; Champlin R; Duvic M; Anderlini P
    Bone Marrow Transplant; 2003 Mar; 31(6):459-65. PubMed ID: 12665841
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A comparison of the therapeutic effects between related donor and unrelated donor allogeneic hematopoietic stem cell transplantation in treatment of leukemia].
    Yang K; Liu QF; Fan ZP; Sun J; Xu D; Wei YQ; Zhang Y; Meng FY
    Zhonghua Nei Ke Za Zhi; 2007 Feb; 46(2):135-9. PubMed ID: 17445441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.